Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

CGTX Cognition Therapeutics, Inc. Common Stock
$0.64 -6.03% -0.04
Notify me if price changes either direction
Interactive Brokers Logotype

Buy CGTX stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades

Cognition Therapeutics, Inc. Common Stock (CGTX)

Loading

Key Stats

Market cap. 60.8M
Enterprise value 34.4M
Trailing PE -1.9837500527501
Forward PE -3.4529731
PEG Ratio 0.031173215114645
Enterprise to EBITDA -0.915
Price to book MRQ 2.074026

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-06-30
EBITDA -37557000
Diluted EPS TTM -0.16
Total Cash (MRQ) 30.8M
Current ratio (MRQ) 6.677
Operating Cash Flow (TTM) -15291000

CGTX trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent CGTX News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.